This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results